Scarica l'app Stockscreener
4.13
1.10%
0.045
Dopo l'orario di chiusura:
4.06
-0.07
-1.69%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
X 4 Pharmaceuticals Inc Borsa (XFOR) Ultime notizie
Form 4 Shuttle Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
X4 Pharmaceuticals CFO David Kirske sells $36,428 in common stock By Investing.com - Investing.com Canada
Form 4 X4 Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
Form 4 Processa Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
X4 Pharmaceuticals (XFOR) CFO sells 8,543 shares to cover RSU tax - Stock Titan
Director Kelly Gold granted 110,000 X4 Pharmaceuticals (XFOR) stock options at $4.085 - Stock Titan
X4 Pharmaceuticals (XFOR) director Gold Kelly files initial Form 3 ownership - Stock Titan
Kelly Gold joins X4 Pharmaceuticals (Nasdaq: XFOR) board and Audit Committee - Stock Titan
X4 Pharmaceuticals Announces Appointment of Kelly Gold as an Independent Director and Member of the Audit Committee, Effective July 1, 2026 - marketscreener.com
Form 4 Adial Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue - The Manila Times
X4 Pharmaceuticals appoints Kelly Gold to board of directors By Investing.com - Investing.com Canada
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors - The Manila Times
X4 Pharmaceuticals adds CAMP4 CFO Kelly Gold to its board - Stock Titan
Form 4 Ionis Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Canada
Form 4 Processa Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Canada
Form 4 Eton Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Nigeria
Form 4 Vertex Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Canada
Form 4 Tarsus Pharmaceuticals Inc For: 29 June By Investing.com - Investing.com South Africa
Form 4 ACADIA Pharmaceuticals Inc For: 29 June By Investing.com - Investing.com South Africa
Cadrenal Therapeutics (NASDAQ: CVKD) names interim CFO and realigns board classes - Stock Titan
Universe Pharmaceuticals (NASDAQ:UPC) pop puts $10.75M patent deal and float in focus - TechStock²
6,000 vTv Therapeutics (VTVT) options granted to director tied to Baker funds - Stock Titan
Tarsus Pharmaceuticals (TARS) director receives RSU and stock option grants - Stock Titan
Following Satri Cel Approval Is CARsgen Therapeutics Holdings (SEHK:2171) Fully Priced? - simplywall.st
Is Alnylam Pharmaceuticals (ALNY) Undervalued Following Its Expanded Komodo Health AI Partnership? - simplywall.st
X4 Pharmaceuticals, Inc.(NasdaqCM: XFOR) added to Russell 2000 Index - marketscreener.com
Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation? - TradingView
Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today - TradingView
X4 Pharmaceuticals, Inc.(NasdaqCM: XFOR) added to Russell 2000 Value Benchmark - marketscreener.com
Nephrotic Syndrome Market Set for Robust Growth During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Research | DelveInsight - PR Newswire
Form DEF 14C Curanex Pharmaceuticals Inc For: 29 June By Investing.com - Investing.com Canada
X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) added to Russell Microcap Value Benchmark Index - marketscreener.com
Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom - Investing News Network
Xilio Therapeutics taps biotech veteran Ben Harshbarger as legal chief - Stock Titan
BioCryst (NASDAQ: BCRX) lowers 2026 expenses and closes Birmingham R&D hub - Stock Titan
Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases - PR Newswire
5 Biotech Stocks That Skyrocketed 105% To 235% — TWST, INDV, MIRM & More - RTTNews
X4 Pharmaceuticals, Inc.(NasdaqCM: XFOR) added to Russell Microcap Index - marketscreener.com
Is Spyre Therapeutics (SYRE) Fully Valued After Russell Index Removal And A $500 Million Offering? - simplywall.st
Pfizer’s CFO Just Left and a Key Drug Trial Missed. Here’s What That Means for PFE Stock in 2026 - TIKR.com
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP - BioSpace
X4 Pharmaceuticals, Inc.(NasdaqCM: XFOR) added to Russell 2500 Index - marketscreener.com
BridgeBio's achondroplasia drug posts NEJM Phase 3 data - Stock Titan
XFOR Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 ARS Pharmaceuticals Inc For: 26 June By Investing.com - Investing.com Nigeria
Cadrenal Therapeutics (CVKD) CEO Quang Pham sells 11,156 shares under 10b5-1 plan - Stock Titan
Form 4 Ionis Pharmaceuticals Inc For: 26 June By Investing.com - Investing.com Nigeria
BVF group sells 1,630,658 Kymera (KYMR) shares in joint Form 4 - Stock Titan
Form 144 IONIS PHARMACEUTICALS INC For: 26 June By Investing.com - Investing.com Canada
ARS Pharmaceuticals (NASDAQ: SPRY) grants 30,000 options to RA Capital-linked director - Stock Titan
Director Rajeev Dadoo granted 30,000 ARS Pharmaceuticals (SPRY) stock options - Stock Titan
ARS Pharmaceuticals (SPRY) director Laura Shawver receives 30,000 stock options award - Stock Titan
ARS Pharmaceuticals (SPRY) director Saqib Islam granted 30,000 stock options at $10.54 - Stock Titan
Universe Pharmaceuticals (NASDAQ: UPC) to acquire Best Praise in US$10.75M all-share patent deal - Stock Titan
Universe Pharmaceuticals bets $10.8M on five China patents - Stock Titan
[144] ACADIA PHARMACEUTICALS INC SEC Filing - Stock Titan
Form DEF 14A Amneal Pharmaceuticals Inc Class A For: 26 June - Investing.com Canada
X4 Pharmaceuticals updates investor plans, shares remain thinly traded on Nasdaq - AD HOC NEWS
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP - Via TT
48Q0 Forecast — Price Target — Prediction for 2027 - TradingView
X4 Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:XFOR) - TradingView
A3E4QR Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 Rhythm Pharmaceuticals Inc For: 25 June By Investing.com - Investing.com Canada
X4 Pharmaceuticals, Thursday trading bias in shares - Ad-hoc-news.de
Form 4 Rigel Pharmaceuticals Inc For: 24 June By Investing.com - Investing.com Canada
3.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):